Shuttle Pharmaceuticals Holdings, Inc. (SHPH): Nasdaq/NYSE listing notice — Shuttle Pharma receives Nasdaq bid price deficiency notice; 180-day cure period until June 30, 2025

Shuttle Pharmaceuticals Holdings, Inc.

Received Nasdaq letter Dec 31, 2024 for failing to maintain minimum $1.00 bid price for 30 consecutive business days.
Has 180 calendar days until June 30, 2025 to regain compliance by closing bid price >= $1.00 for 10 consecutive business days.
If not compliant by June 30, may be eligible for additional 180-day period if meeting other listing standards and intending to cure via reverse stock split.
Listing continues under symbol SHPH; company considering available options to regain compliance.
CEO to participate in Lytham Partners fireside chat on Jan 13, 2025; plans to discuss Ropidoxuridine Phase 2 trial and Shuttle Diagnostics.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 30, 2024 the Company’s common stock had failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days, or until June 30, 2025 (the “Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum o

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.7

Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 30, 2024 the Company’s common stock had failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-001132

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.